Q32 Bio Newsroom

Q32 Bio Is Maintained at Outperform by BMO Capital

Dow JonesDec 13 00:27

BMO Capital Maintains Q32 Bio(QTTB.US) With Buy Rating, Cuts Target Price to $22

Futu NewsDec 12 23:32

Q32 Bio Cut to Neutral From Buy by Guggenheim

Dow JonesDec 12 23:25

Q32 Bio Analyst Ratings

BenzingaDec 12 23:14

Guggenheim Downgrades Q32 Bio(QTTB.US) to Hold Rating

Futu NewsDec 12 00:31

Q32 Bio Is Maintained at Overweight by Piper Sandler

Dow JonesDec 11 21:20

Piper Sandler Maintains Overweight on Q32 Bio, Lowers Price Target to $20

BenzingaDec 11 21:10

Q32 Bio (QTTB) Receives a Buy From Oppenheimer

TipRanksDec 11 20:52

Piper Sandler Reaffirms Their Buy Rating on Q32 Bio (QTTB)

TipRanksDec 11 19:47

Raymond James Downgrades Q32 Bio to Outperform, Lowers Price Target to $22

BenzingaDec 11 19:17

Q32 Bio Analyst Ratings

BenzingaDec 11 19:16

Q32 Bio Initiated at Outperform by BMO Capital

Dow JonesDec 6 19:29

Q32 Bio Analyst Ratings

BenzingaDec 6 19:19

BMO Capital Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $64

Futu NewsDec 6 06:31

Positive Outlook for Q32 Bio: Buy Rating Backed by Promising Clinical Timelines and Increased Price Target

TipRanksNov 11 14:31

Wells Fargo Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $95

Futu NewsNov 5 18:40

Oppenheimer Maintains Q32 Bio(QTTB.US) With Buy Rating, Raises Target Price to $80

Futu NewsOct 16 20:31

Q32 Bio Analyst Ratings

BenzingaSep 11 20:54

Wells Fargo Initiates Q32 Bio at Overweight With $95 Price Target

MT NewswiresSep 11 19:35

Wells Fargo Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $95

Futu NewsSep 11 18:33